784

Phospho-HER3/ErbB3 (Tyr1222) (50C2) Rabbit mAb



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 185	Source/Isotype: Rabbit IgG	UniProt ID: #P21860	Entrez-Gene Id: 2065		
Product Usage Information		Application Western Blotting		Dilution 1:1000				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				ol and less than		
Specificity/Sensitivity		Phospho-HER3/ErbB3 (Tyr1222) (50C2) Rabbit mAb detects endogenous HER3/ErbB3 proteins only when phosphorylated at tyrosine 1222. The antibody does not cross-react with other tyrosine phosphorylated receptor tyrosine kinases.						
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1222 of human HER3/ErbB3.						
Background		HER3/ErbB3 is a member of the ErbB receptor protein tyrosine kinase family, but it lacks tyrosine kinase activity. Tyrosine phosphorylation of ErbB3 depends on its association with other ErbB tyrosine kinases. Upon ligand binding, heterodimers form between ErbB3 and other ErbB proteins, and ErbB3 is phosphorylated on tyrosine residues by the activated ErbB kinase (1,2). There are at least 9 potential tyrosine phosphorylation sites in the carboxy-terminal tail of ErbB3. These sites serve as consensus binding sites for signal transducing proteins, including Src family members, Grb2, and the p85 subunit of PI3 kinase, which mediate ErbB downstream signaling (3). Both Tyr1222 and Tyr1289 of ErbB3 reside within a YXXM motif and participate in signaling to PI3K (4).						
		Investigators have found that ErbB3 is highly expressed in many cancer cells (5) and activation of the ErbB3/PI3K pathway is correlated with malignant phenotypes of adenocarcinomas (6). Research studies have demonstrated that in tumor development, ErbB3 may function as an oncogenic unit together with other ErbB members (e.g., ErbB2 requires ErbB3 to drive breast tumor cell proliferation) (7). Thus, investigators view inhibiting interaction between ErbB3 and ErbB tyrosine kinases as a novel strategy for anti-tumor therapy.						
Background R	d References 1. Yarden, Y. and Sliwkowski, M.X. (2001) Nat Rev Mol Cell Biol 2, 127-37. 2. Guy, P.M. et al. (1994) Proc Natl Acad Sci U S A 91, 8132-6. 3. Songyang, Z. et al. (1993) Cell 72, 767-78. 4. Kim, H.H. et al. (1994) J Biol Chem 269, 24747-55. 5. Sithanandam, G. et al. (2003) Carcinogenesis 24, 1581-92. 6. Kobayashi, M. et al. (2003) Oncogene 22, 1294-301. 7. Holbro, T. et al. (2003) Proc Natl Acad Sci U S A 100, 8933-8.							
Species Reacti	vity	Species reactivity is de	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot I	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				ו 5% w/v nonfat		
Applications K	ley	W: Western Blotting						
Cross-Reactivi	ty Key	H: Human M: Mouse						
Trademarks a	nd Patents							
		All other trademarks a more information.	are the property of	their respective owners.	Visit cellsignal.com	/trademarks for		

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.